The US Food and Drug Administration’s final guidance on nonclinical studies to support drug applications for smoking cessation or similar indications is largely unchanged from the draft, which signaled the extent of the agency’s interest in novel nicotine replacement therapy products, such as e-cigarettes.
The final guidance announced on 28 October tracks nearly word-for-word with the draft document detailing the agency’s thinking on...




